← Back to patent-cliff list
Tosposertib phosphate
Tier C — Watch / tradeTosposertib phosphate
TiumBio Co Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：TGF-β2, TGFBR1, VEGFR2
Indications (approved)：Solid tumour, Idiopathic pulmonary fibrosis
Regional status
US
Phase II
2021-12-02
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Tosposertib phosphate?
Approved indications include: Solid tumour, Idiopathic pulmonary fibrosis.
When does the Tosposertib phosphate patent expire?
No public expiry year is available for Tosposertib phosphate yet; this page updates once verified.
How do I get a quote for Tosposertib phosphate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21